RT Journal Article
T1 Impact of periodontal therapy on systemic markers of inflammation in patients with metabolic syndrome: a randomized clinical trial
A1 Montero Solís, Eduardo
A1 López Durán, Mercedes
A1 Vidal, Honorato
A1 Martínez Ferrero, María
A1 Virto Ruiz, Leire
A1 Marrero, Jorge
A1 Herrera González, David
A1 Zapatero, Antonio
A1 Sanz Alonso, Mariano
AB Aim: To determine the impact of periodontal treatment on systemic markers of inflammation in patients with metabolic syndrome (MetS) and periodontitis.Materials and methods: In this parallel-arm, double-blind, randomized controlled clinical trial, 63 patients with MetS and severe periodontitis were randomly assigned to receive either intensive periodontal treatment (IPT; scaling and root planing plus azithromycin 500 mg every day for 3 days) or minimal periodontal treatment (MPT; supragingival professional mechanical plaque removal plus a placebo). The primary outcome was the impact of the tested interventions on high-sensitivity C-reactive protein (hs-CRP) serum levels at 6 months. As secondary outcomes, differences in the levels of cytokines, markers of prothrombotic states, carbohydrate and lipid metabolism, as well as blood pressure, were measured at 3 and 6 months after therapy.Results: The intention-to-treat population consisted of 63 subjects randomly assigned to either the MPT (n = 31) or the IPT (n = 32) group. At baseline, mean hs-CRP was 3.9 mg/L (standard deviation [SD] = 2.9) and 3.9 mg/L (SD = 3.4), respectively, and no significant differences in cardiometabolic risk profiles were detected between the groups. Adjusting for baseline hs-CRP, sex, age, smoking status and body mass index, hs-CRP at 6 months was 1.2 mg/L (95% CI 0.4; 2.0; P = .004) lower in the IPT group than in the MPT group. In the secondary outcomes, significant reductions in IL-1β, TNF-α, HbA1c and blood pressure were observed in the IPT group at 3 months compared with the MPT group.Conclusion: Effective periodontal treatment significantly reduced hs-CRP after 6 months in patients with MetS and severe periodontitis. Periodontal therapy might be useful to reduce cardiovascular risk in these patients.
PB Wiley
SN 1462-8902
YR 2020
FD 2020
LK https://hdl.handle.net/20.500.14352/94133
UL https://hdl.handle.net/20.500.14352/94133
LA eng
NO Montero E, López M, Vidal H, Martínez M, Virto L, Marrero J, Herrera D, Zapatero A, Sanz M. Impact of periodontal therapy on systemic markers of inflammation in patients with metabolic syndrome: A randomized clinical trial. Diabetes Obes Metab. 2020 Nov;22(11):2120-2132.
NO Universidad Complutense de Madrid 
DS Docta Complutense
RD 6 abr 2025